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Abstract
Background: The relation between fetal growth retardation and cardiovascular and metabolic diseases
in later life has been demonstrated in many studies. However, debate exists around the potential
independent role of postnatal growth acceleration. Furthermore, it is unknown whether a potential effect
of growth acceleration on cardiovascular and metabolic function is confined to certain timeframes.
The present study assesses the (predictive) role of prenatal and postnatal growth on 5 components of
cardiovascular and metabolic function in children aged 5. The potential association of timing of postnatal
growth acceleration with these outcomes will be explored.
Methods and design: Prospective multiethnic community-based cohort study of 8266 pregnancies
(Amsterdam Born Children and their Development, ABCD study). Up till now, anthropometry of 5104
children from the original cohort was followed during the first 5 years of life, with additional information
about birth weight, pregnancy duration, and various potential confounding variables.
At age 5, various components of cardiovascular and metabolic function are being measured. Outcome
variables are body size, body composition and fat distribution, insulin sensitivity, lipid profile, blood
pressure and autonomic regulation of cardiovascular function.
Discussion: This study will be one of the first population-based prospective cohort studies to address the
association between measures of both prenatal and postnatal growth and various components of
cardiovascular and metabolic function. Specific attention is paid to the timing of acceleration in growth and
its potential association with the outcome variables. Importantly, the longitudinal design of this study gives
us the opportunity to gain more insight into growth trajectories associated with adverse outcomes in later
life. If identified as an independent risk factor, this provides further basis for the hypothesis that accelerated
growth during the first years of life is a modifiable factor for the prevention of cardiovascular and metabolic
disorders in later life. Moreover, identification of specific vulnerable periods during development may
reveal suitable timeframes for early interventions.
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Although it is clear that genetic factors contribute to the
propensity towards obesity and associated conditions, the
dramatic increase in prevalence in the last decades under-
lines the role of environmental determinants. Recent find-
ings associated with the hypothesis of Developmental
Origins of Health and Disease (DOHaD) have pointed
out that cardiovascular and metabolic diseases may origi-
nate from periconceptional and perinatal environmental
factors.[1,2] More specifically, a series of epidemiological
studies in several countries has documented that subjects
with fetal growth retardation due to intrauterine malnutri-
tion have a higher risk of developing hypertension, obes-
ity, diabetes and coronary heart disease in later life. [3-10]
In addition, prematurity has recently been demonstrated
as an independent risk factor for high blood pressure and
cardiovascular diseases in later life.[11] Furthermore,
evolving evidence suggests an independent role of rapid
postnatal growth (also referred to as "catch-up growth")
on cardiovascular and metabolic diseases in later life (the
so called accelerated growth hypothesis). Rapid growth in
postnatal life may be driven by the aim to compensate for
antenatal growth retardation or prematurity which may
subsequently increase the adverse effect on cardiovascular
disease risk in later life.[3,5,7,12-14] However, the occur-
rence of accelerated postnatal growth is not limited to
babies born growth retarded or premature, it also occurs
in full term, normal birth weight infants, with comparable
adverse associations with cardiovascular and metabolic
function in later life.[15]
The exact timing of growth acceleration incurring associ-
ated cardiovascular and metabolic diseases has not been
established unequivocally. It is plausible that the moment
of occurrence is of greater importance than the magnitude
of growth acceleration itself. [16-19] Studies addressing
this subject are inconclusive. While Singhal et al. and Ong
et al. reported an adverse effect of accelerated infant
growth on cardiovascular and metabolic function, the
Helsinki observations showed that the combination of
slow growth in utero, low weight gain in infancy (thinness
at 1 year) and growth acceleration in childhood is a strong
predictor of coronary heart disease.[6,8,18,20,21]
The pathophysiological mechanisms linking early growth
and cardiovascular and metabolic function in later life
remain elusive. Impaired fetal growth as such may not be
the cause of the long-term consequences, but rather con-
stitute a marker of a coordinated fetal response to a
restricted intrauterine environment. This coordinated
fetal response may result in persistent alterations in phys-
iologic and metabolic homeostatic set points, which in a
rich extrauterine environment may be followed by accel-
erated postnatal growth and subsequent increased risk of
cardiovascular and metabolic diseases in later life. Nota-
bly, fetal growth retardation may not always be ade-
quately represented by a reduced birth weight.[1]
Moreover, retarded fetal growth may be associated with
alterations in organ development which in turn are asso-
ciated with adult cardiovascular and metabolic diseases.
This may be enhanced if retarded fetal growth is followed
by accelerated postnatal growth. More specifically, associ-
ations have been found between fetal growth retardation
and a reduction in the number of nephrons[22] (associ-
ated with hypertension), reduced abdominal circumfer-
ence[23] (as an indication of liver size and cholesterol
regulation), and a reduction in the number of pancreatic
β cells[24] (leading to decreased production of insulin,
and potentially to type 2 diabetes). Also, thinness at birth
may be associated with abnormalities in muscle structure
and function which may have long term consequences
that interfere with insulin's ability to promote glucose
uptake in skeletal muscle (leading to insulin resist-
ance).[25]
If identified as an independent risk factor in community
based studies, accelerated growth during the first years of
life may be an important modifiable factor for the preven-
tion of obesity, and other cardiovascular and metabolic
diseases in later life.
Hypotheses
Primary outcome variable
• Impaired intrauterine growth, with subsequent
accelerated growth during the immediate postnatal
period, infancy and childhood is an independent
determinant of body size (BMI), body composition
(fat percentage, fat-free mass) and fat distribution
(waist circumference, waist-to-height-ratio) at the age
of 5.
Secondary outcome measures
• Impaired intrauterine growth, with subsequent
accelerated growth during the immediate postnatal
period, infancy and childhood is an independent
determinant of insulin sensitivity at the age of 5.
• Impaired intrauterine growth, with subsequent
accelerated growth during the immediate postnatal
period, infancy and childhood is an independent
determinant of lipid profile at the age of 5.
• Impaired intrauterine growth, with subsequent
accelerated growth during the immediate postnatal
period, infancy and childhood is an independent
determinant of blood pressure at the age of 5.
• Impaired intrauterine growth, with subsequent
accelerated growth during the immediate postnatal
period, infancy and childhood is an independentPage 2 of 8
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lar function at the age of 5.
Aims
• To examine the role of fetal growth (retardation) and
subsequent (accelerated) postnatal growth on 5 differ-
ent components of cardiovascular and metabolic func-
tion at 5 years, incorporating potential effect-
modifying variables like gender and prematurity and
various potential confounding variables.
• To determine the time period of postnatal growth
acceleration which is most associated with these com-
ponents of cardiovascular and metabolic function.
Methods and design
Procedure (figure 1)
Phase I and II
The ABCD study is a prospective cohort study, a collabo-
rative effort of the Municipal Health Service (GGD), all
hospitals and midwife practices in Amsterdam and a
research group hosted at the GGD/Amsterdam Medical
Centre (AMC)/VU university medical centre Amsterdam
(VUmc). The study focuses on the explanatory role of life-
style and dietary habits during pregnancy in birth out-
comes and future health of the child, with specific
attention to ethnicity http://www.abcd-study.nl.
Between January 2003 and March 2004, all pregnant
women living in Amsterdam were invited to participate in
this study at their first visit to an obstetric caregiver. A
questionnaire, covering sociodemographic data, obstetric
history, lifestyle, dietary habits, and psychosocial factors,
was sent to the pregnant woman's home address, this was
2 weeks after their fist visit (12–14th week of pregnancy).
Questionnaires were returned by 8.266 women (response
rate: 67%). From this group 7.863 gave birth to a viable
singleton infant.
Pregnancy duration, gender and birth weight were
obtained from Youth Health Care centres which perform
neonatal screening on congenital inborn errors of metab-
olism in all Dutch newborns. A standardised birth weight
was calculated using the most recent Dutch reference val-
ues obtained from the Dutch perinatal registration http://
www.perinatreg.nl. Birth weight was standardised for gen-
der, pregnancy duration and parity. Birth weight SDS is
interpreted as an expression of intrauterine growth.
Three months after delivery another questionnaire was
sent to the mothers who had given permission to follow
the health status of the child for further research (n =
6.735) with questions concerning the course of pregnancy
and delivery, questions about health, development and
growth of the baby, and questions about lifestyle of the
mother during and after pregnancy. With 5.131 women
returning the questionnaire the response rate was 76%.
Until the age of 14 months length and weight of these
children were routinely collected at the Youth Health Care
registration of the Public Health Service in Amsterdam.
These measurements took place during on average 9 regu-
lar follow-up moments and were performed by well
trained nurses.
6.575 mothers gave permission to follow up the growth
data of their child. Up till now, growth data of 5.104 of
these children are digitized.
Phase III
Phase three of the study has started in the summer of
2008. Around two weeks after their ABCD-child's 5th
birthday, mothers who had initially given permission for
follow up are sent a questionnaire in which they are also
asked for permission on participation of their child in the
ABCD health check.
Two weeks before the health check mothers receive a noti-
fying letter and an additional self administered food fre-
quency questionnaire (FFQ).
The health check is situated at the children's primary
school (which are located all over Amsterdam). One half
hour before the school begins a blood sample is taken
from the children by finger prick. The various measure-
ments take place during the rest of the day.
Outcome variables and potential confounding and effect 
modifying variables (table 1)
Questionnaires
The general ABCD-questionnaire contains items about
the child's health, development and behaviour (i.e. phys-
ical exercise, sedentary behaviour, amount of sleep, and
the Child Feeding Questionnaire (CFQ).[26] Further-
more, it contains items regarding mother's attitude
towards the child's weight, maternal lifestyle and parents'
and grandparents' history of cardiovascular (CVD) and
metabolic disorders.
The FFQ is developed by TNO Food (Zeist, the Nether-
lands). It consists of 77 food items, for which the fre-
quency of consumption and portion size are to be
estimated. Results of a validation study comparing the
TNO-FFQ with the gold standard doubly labelled water
are promising; the Pearson correlation coefficient
between energy intake (TNO-FFQ) and energy expendi-
ture was 0.62 (to be published).Page 3 of 8
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ProcedureFigure 1
Procedure.
12.373 pregnant women approached
8.266 pregnancy questionnaire (response rate 67%)
7.863 viable singleton infants
5.131 neonatal questionnaire (response rate 76%)
5.104 growth data digitalized untill 14 mo
Phase I 
general ABCD questionnaire
food frequency questionnaire
ABCD health check
blood samples
measurements
Phase III
Phase II 
6.735 permission for follow up (86%)
6.575 permission for collecting growth data (84%)
BMC Pediatrics 2009, 9:23 http://www.biomedcentral.com/1471-2431/9/23Blood sampling and processing
Capillary blood is collected in a well validated collection
kit which is developed for ambulatory purposes (Deme-
cal, Haarlem, The Netherlands).[27] Fasting plasma glu-
cose (Gluc), C-peptide, total cholesterol (TC), high
density lipoprotein cholesterol (HDL) and triglycerides
(TG) are determined.
Outcome measures are Gluc, insulin resistance and β-cell
function (HOMA-IR, HOMA-%B)[28], TC, HDL and TG
(mmol/dl).
Anthropometrics
Height (Ht) is measured to the nearest millimetre using a
Leicester portable height measure (Seca), and weight (Wt)
to the nearest 100 gram using a Marsden weighing scale,
model MS-4102. Waist circumference (WC) is measured
midway between the costal border and the iliac crest to
the nearest millimetre using a Seca measuring tape.
Outcome measures are WC, expressed in cm, waist-to-
height ratio (WHtR) and body mass index (BMI). BMI is
calculated as the individual's weight in kilograms divided
by their height in meters squared.
Bioelectrical impedance analysis
Arm-to-leg bioelectrical impedance analysis (BIA) is
measured twice using the Bodystat 1500 MDD machine
(Bodystat Inc, Douglas, UK). Body fat percentage (Fat%)
is calculated using the following equations, adapted from
Kushner et al.[29] and Lohman.[30]:
TBW = 0,59 Ht2/R50 + 0,065 Wt +0,04 (1)
FFM = c TBW (2)
Fat % = ((Wt - FFM)/Wt) * 100% (3)
In which TBW is total body water, R50 is resistance at 50
kHz, FFM is fat free mass and c is 1,30 (100/77) for males
and 1,28 (100/78) for females.
Outcome measures are Fat% and FFM.
Blood pressure measurement
Blood pressure is measured 4 times on the right arm: 2
times in a supine position after 5 minutes of rest and 2
times in a sitting position after 5 minutes of rest. The
device used is the Omron 705 IT (Omron Healthcare Inc,
Bannockburn, IL, USA) with its small cuff (arm circumfer-
ence 17–22 cm).
Table 1: Outcome variables and potential confounding/effect modifying variables
Cardiometabolic risk profile Direct outcome
variables
Derived outcome variables Potential confounding/effect modifying 
(EM) variables
Body size, body composition and fat 
distribution
WC BMI (primary outcome variable) gender (EM)
WHtR prematurity (EM)
Fat% Family history positive for CVD or metabolic 
diseases
FFM maternal smoking
maternal and paternal BMI
Insulin sensitivity Gluc HOMA-IR maternal educational level and cohabitant 
status
HOMA-%B physical exercise
sedentary behaviour
Lipid profile TC amount of sleep
HDL caloric intake
TG eating behaviour
maternal attitude towards child weight
Blood pressure SP MAP
DP
Autonomic regulation of cardiovascular 
function
HR
RMSSD
PEP
BMI = body mass index; CVD = cardiovascular disease; DP = diastolic blood pressure; Fat% = fat percentage; FFM = fat-free mass; Gluc = fasting 
plasma glucose; HDL = high density lipoprotein cholesterol; HOMA-IR = homeostasis model assessment-insulin resistance; HOMA-%B = 
homeostasis model assessment β cell function; HR = heart rate; MAP = mean arterial pressure; PEP = pre ejection period; RMSSD = root mean 
square of successive inter beat intervals; SP = systolic blood pressure; TC = total cholesterol; TG = triglycerides; WC = waist circumference; 
WHtR = waist-height-ratioPage 5 of 8
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pressure (DP), and mean arterial pressure (MAP), all
expressed in mmHg.
MAP is calculated using the following equation:
MAP = DP + 1/3 (SP-DP)
Measurement of autonomic regulation of cardiovascular function
Heart rate (HR), root mean square of successive inter beat
intervals (RMSSD) and pre ejection period (PEP) are dif-
ferent measures of cardiac autonomic control which can
be obtained non-invasively and in an ambulatory setting
with various devices. We used the VU University Ambula-
tory Monitoring System (VU-AMS) to assess the various
measures, in a supine position during 7 minutes after 1
minute of rest and in a sitting position during 7 minutes
after 1 minute of rest. The VU-AMS continuously records
an electrocardiogram (ECG) and an impedance cardio-
gram (ICG).
Reliability and validity aspects and recording methodol-
ogy of the VU-AMS have been described previously.[31] A
continuous time series of R wave to R wave intervals is
derived on line from a three lead ECG. HR can be directly
derived from the time between two adjacent R waves.
Vagal tone is assessed by the root mean square of succes-
sive differences in these interbeat intervals (RMSSD), that
has previously been proven to be a valid index of vagal
tone. (task force, 1996). The ICG is obtained by 4 elec-
trodes. The B-point signals the opening of the aortic valves
and is scored in the ICG signal. PEP is the time interval
between the onset of ventricular depolarisation (the Q
wave onset in the ECG) and the opening of the aortic
valves (B-point in ICG) and is considered to be an ade-
quate surrogate measure for sympathic nervous system
activity.[31]
Data handling and statistical analysis
Data analysis for 5 outcomes of cardiovascular and metabolic 
function
Similar to other studies analysing growth trajectories, fol-
low-up in growth (weight and height) is divided in 3 time
periods for each individual: immediate growth (between
1 and 6 months), infant growth (between 6 months and
14 months), and childhood growth (between 14 months
and 5 years) [17]. For each time period the average stand-
ardised growth velocity is calculated by subtracting the
standardized weight or height at the earlier moment in
time from the standardized weight or height at the later
moment in time, resulting in a ΔSDS. Dutch reference
standards are used in expressing weight and height as
standard deviation scores (SDS).[32] Growth acceleration
in weight and height, respectively, are both defined as
ΔSDS>0.67. SDS 0.67 represents the width of each percen-
tile band on standard growth charts (that is P2–P9, P9–
P25, P25–P50, etc), and consequently this is the most
commonly used indicator of clinically significant acceler-
ated growth.[14,33]
Analysis of the 5 years outcome measures are undertaken
using linear and/or logistic regression with the 4 random
effects (standardised birth weight, and ΔSDS (standard-
ised growth velocity) for each of the 3 time periods) as
exposures (expressed as continuous variables). We will
examine the effects of fetal and postnatal growth (both
weight and height) with 3 models to account for potential
confounders: (1) mutual adjustment for all of the growth
measures; (2) as in model 1 but with the addition of con-
founding variables, to be determined by univariate analy-
sis; (3) as in model 2 but with the addition of potential
effect modifiers (gender and prematurity), to be deter-
mined by assessment of interaction.
All aforementioned analyses are repeated with the expo-
sure variables dichotomised; standardised birth weight is
divided in > and ≤ average and standardised growth veloc-
ity (ΔSDS) in > and ≤ 0.67.
Power analysis
For power calculations BMI is chosen as the primary out-
come variable. Based on 90% power (1-β), to detect a 0.5
point difference in BMI between children with and with-
out growth acceleration in weight (α = 0.05, two-sided), a
total of 850 children are required. In the calculation we
have accounted for the prevalence of accelerated growth
in weight in the first 6 months, which in our population
is around 19%. In comparison, Karaolis-Danckert et al.
found a prevalence of growth acceleration of around 29%
in the first two years of life.[15]
Inclusion/exclusion criteria
Multiple births were excluded from the analysis.
Ethics
Approval of the study was obtained from the Central
Committee on Research involving Human Subjects in the
Netherlands, the Medical Ethical Committees of partici-
pating hospitals, and from the Registration Committee of
the Municipality of Amsterdam.
Discussion
Emerging evidence indicates that adult degenerative dis-
eases are related to different patterns of fetal, infant, and
childhood growth. Retarded growth during fetal life and
accelerated weight gain during infancy and childhood
appear to be associated with the development of cardio-
vascular disease and type 2 diabetes in adult life. Unfortu-
nately it is not clear what optimal growth is and how it can
be achieved. Although deviations from normal earlyPage 6 of 8
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for adult disease, they are not causative factors as such. As
early life risk factors, they are to a large degree modified by
various variables during childhood and adult life.
Our study is one of the first large population based pro-
spective cohort studies which will address the association
of prenatal growth retardation and postnatal growth
acceleration with outcome variables including various
components of cardiovascular and metabolic function.
Specific attention is paid to the exact timing of growth
acceleration and its association with these outcome varia-
bles. Importantly, the longitudinal design of this study
offers us the opportunity to gain more insight into growth
trajectories associated with adverse outcomes in later life.
Several well-established components of (albeit adult) car-
diovascular and metabolic function will be addressed in
our study, including obesity, insulin sensitivity, lipid pro-
file and blood pressure. As obesity in children is not easy
to determine and cut-off values vary with age, we will
address body composition (fat mass and fat-free mass)
and fat distribution (waist circumference and waist-
height-ratio) in addition to BMI. Furthermore, the associ-
ation of autonomic regulation of cardiovascular function
with different patterns of growth in early life will be
assessed. To our knowledge, this is innovative in the field
of cardiovascular research. If an association is established,
this suggests that changes in autonomic regulation may be
important in linking early life factors and cardiovascular
diseases in later life.
If identified as an important independent risk factor in
this large community based study, this provides further
ground for the hypothesis that accelerated growth during
the first years of life comprise an important modifiable
factor for the prevention of obesity, and other cardiovas-
cular and metabolic diseases in later life. Moreover, iden-
tification of vulnerable periods during development may
reveal suitable timeframes for early interventions.
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